ClinicalTrials.gg
CompletedNCT00525044Updated Jul 11, 2019Results posted

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

A Phase 3 interventional study of Ambroxol and Placebo in Pharyngitis, sponsored by Boehringer Ingelheim. Completed at 4 sites in China. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-11.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Study summary

The aim of this trial is to investigate the efficacy and tolerance of Ambroxol lozenges 20 mg in the treatment of sore throat in patients with acute viral pharyngitis.

Read the detailed description

Male and female ambulant patients complaining of a sore throat caused by acute viral pharyngitis. Every patient may be included in the trial only once. A total of 250 male and female ambulant patients between the ages of 18 and 65 years will be enrolled. Approximately 8 centers will be recruited each enrolling approximately 30-32 patients.

Study Hypothesis:

The two-sided test hypothesis, that the results of the active treatment group with 20 mg Ambroxol and the placebo group do not differ with regard to the primary endpoint (null hypothesis (H0) will be tested against the alternative (H1) that they are not equal.

Comparison(s):

PRIMARY ENDPOINT:

Indication of pain on the VRS (PI)-verbal rating scale (pain intensity)-in the first 3 hours (the patient rates his/her pain on a six-point verbal rating scale).

SECONDARY ENDPOINT (S):

  1. Patient's assessment of effectiveness and tolerance. The patient assesses the effectiveness and the tolerance of the test medicine for treating his sore throat at the end of the first and second day of treatment, by means of a verbal rating scale.
  2. Participating doctors assessment of tolerance.
02

Conditions studied

  • Pharyngitis

Browse trials for

03

In context

Pharyngitis

227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.

This study's enrollment of 249 is above the median of 144 across 189 interventional studies indexed under Pharyngitis.

Browse Pharyngitis studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Patients having a sore throat with acute viral pharyngitis. 2. Female and male ambulant patients between the ages of 18 and 65. 3. The throat pain intensity is rated at least severe on the VRS (PI). 4. Written is given by the patient. 5. Compliance by the patient seems guaranteed.
  1. Patients with symptoms of primarily bacterial pharyngitis or bacterial secondary infection (clinical findings; inter alia assessment of exudate).
  2. First indication of symptoms of acute pharyngitis (e.g., sore throat) occurred more than 3 days ago already.
  3. Counting of white blood cell in blood routine examination exceeds 10?109/L.
  4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.
  5. Broncho-motor disorders or concomitant diseases with relatively large quantities of secretion (danger of secretion blockage).
  6. Known to Ambroxol or to auxiliary substances contained in the tablet.
  7. Previous and/or existing tumour condition.
  8. Pregnancy and/or breast-feeding.
  9. Alcohol, and/or drug abuse.
  10. Simultaneous participation in another clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
249 participants (actual)

Study arms

  • Placebo comparator
    Control

    Drug: Placebo

  • Experimental
    Ambroxol

    Drug: Ambroxol

Interventions

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline

    The calculation will be based on the pain intensity (PI) assessment by the patient before and then at (pain intensity difference at 30 minutes (PID30)), (pain intensity difference at 60 minutes (PID60)), (pain intensity difference at 120 minutes (PID120)) and (pain intensity difference at 180 minutes (PID180)) after the 1st lozenge. Using the difference in PI from pre-dose baseline for each time point subsequent to dosing, the SPIDnorm will be calculated as SPIDnorm = (30\*PID30 + 30\*PID60 + 60\*PID120 + 60\*PID180)/(180\*PI (baseline)) The patient rates the intensity of his sore throat pain on a 6-point Verbal Rating Scale (VRS) pain intensity (PI) before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain.

    Time frame: pre-dose baseline and 30, 60, 120, and 180 minutes

Secondary outcomes

  1. Pain Intensity (PI) as Rated on a 6-point VRS by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge

    Pain intensity (PI) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. The patient rates the intensity of his sore throat condition on a 6-point rating scale \[VRS(PI)-verbal rating scale (pain intensity)\] before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain. Adjusted Mean (Standard Error) are presented for this outcome measure.

    Time frame: 0.5, 1, 2 and 3 hours

  2. Pain Intensity Difference From Pre-dose Baseline (PID) as Rated on a 6-point Verbal Rating Scale (VRS) by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge

    Pain intensity difference from pre-dose baseline (PID) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. Adjusted Mean (Standard Error) are presented for this outcome measure.

    Time frame: pre-dose baseline and 0.5, 1, 2 and 3 hours

  3. Assessment of Redness of the Pharyngeal Mucosa by the Investigator on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation

    Assessment of redness of the pharyngeal mucosa by the investigator on a 5-point VRS (normal, slightly red, clearly red, very red, severe inflammation) at pre-dose baseline and at the end-of-study evaluation.

    Time frame: Day 1 and Day 2

  4. Assessment of Patients' Assessment of Effectiveness on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation

    Assessment of Patients' Assessment of Effectiveness on a 5-point VRS ("very good", "good", "neither good nor poor", "not very good", "not at all good") at pre-dose baseline and at the end-of-study evaluation

    Time frame: Day 1 and Day 2

07

Results

Posted Jul 11, 2019

Participant flow

Male or female outpatients, 18 to 65 years of age, suffering from acute viral pharyngitis and throat pain of at least severe intensity were to enter the trial.

Participant flow — Overall Study
MilestoneAmbroxol Lozenges 20 mgPlacebo
Started124125
Completed124124
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimarySum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline

The calculation will be based on the pain intensity (PI) assessment by the patient before and then at (pain intensity difference at 30 minutes (PID30)), (pain intensity difference at 60 minutes (PID60)), (pain intensity difference at 120 minutes (PID120)) and (pain intensity difference at 180 minutes (PID180)) after the 1st lozenge. Using the difference in PI from pre-dose baseline for each time point subsequent to dosing, the SPIDnorm will be calculated as SPIDnorm = (30\*PID30 + 30\*PID60 + 60\*PID120 + 60\*PID180)/(180\*PI (baseline)) The patient rates the intensity of his sore throat pain on a 6-point Verbal Rating Scale (VRS) pain intensity (PI) before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain.

Time frame:
pre-dose baseline and 30, 60, 120, and 180 minutes
Reported as:
Least squares mean · ratio
Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline
ratioAmbroxol Lozenges 20 mgPlacebo
Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First Lozenge Expressed as a Ratio of the Pre-dose Baseline-0.40 ± 0.020-0.34 ± 0.020
Statistical analysis
  • Ambroxol Lozenges 20 mg vs Placebo · ANOVA · p = 0.0156 · Mean difference (final values): -0.07 · 95% CI -0.12 to -0.01Treatment differences (Ambroxol- Placebo)
SecondaryPain Intensity (PI) as Rated on a 6-point VRS by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge

Pain intensity (PI) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. The patient rates the intensity of his sore throat condition on a 6-point rating scale \[VRS(PI)-verbal rating scale (pain intensity)\] before taking the first lozenge and 30, 60, 120 and 180 minutes thereafter, and enters his rating in his patient's diary . The rating scale is as follows: 0=no pain; 1=hardly any pain; 2=slight pain; 3=moderate pain; 4=severe pain; 5=very severe pain. Adjusted Mean (Standard Error) are presented for this outcome measure.

Time frame:
0.5, 1, 2 and 3 hours
Reported as:
Least squares mean · score on a scale
Pain Intensity (PI) as Rated on a 6-point VRS by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge
score on a scaleAmbroxol Lozenges 20 mgPlacebo
30 minutes2.9 ± 0.083.1 ± 0.07
60 minutes2.6 ± 0.082.8 ± 0.08
120 minutes2.3 ± 0.102.7 ± 0.09
180 minutes2.2 ± 0.102.5 ± 0.10
Statistical analysis
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.1280 · Mean difference (final values): -0.2 · 95% CI -0.4 to 0Treatment differences (Ambroxol- Placebo)
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.0417 · Mean difference (final values): -0.2 · 95% CI -0.4 to 0.0Treatment differences (Ambroxol- Placebo)
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.0054 · Mean difference (final values): -0.4 · 95% CI -0.6 to -0.1Treatment differences (Ambroxol- Placebo
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.0201 · Mean difference (final values): -0.3 · 95% CI -0.6 to 0.0Treatment differences (Ambroxol- Placebo
SecondaryPain Intensity Difference From Pre-dose Baseline (PID) as Rated on a 6-point Verbal Rating Scale (VRS) by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge

Pain intensity difference from pre-dose baseline (PID) as rated on a 6-point Verbal Rating Scale (VRS) by the patient at 0.5, 1, 2 and 3 hours after the first lozenge. Adjusted Mean (Standard Error) are presented for this outcome measure.

Time frame:
pre-dose baseline and 0.5, 1, 2 and 3 hours
Reported as:
Least squares mean · score on a scale
Pain Intensity Difference From Pre-dose Baseline (PID) as Rated on a 6-point Verbal Rating Scale (VRS) by the Patient at 0.5, 1, 2 and 3 Hours After the First Lozenge
score on a scaleAmbroxol Lozenges 20 mgPlacebo
30 minutes-1.1 ± 0.08-1.0 ± 0.07
60 minutes-1.4 ± 0.08-1.2 ± 0.08
120 minutes-1.8 ± 0.10-1.4 ± 0.09
180 minutes-1.9 ± 0.10-1.6 ± 0.10
Statistical analysis
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.1280 · Mean difference (final values): -0.2 · 95% CI -0.4 to 0.0Treatment differences (Ambroxol- Placebo)
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.0417 · Mean difference (final values): -0.2 · 95% CI -0.4 to 0.0Treatment differences (Ambroxol- Placebo
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.0054 · Mean difference (final values): -0.4 · 95% CI -0.6 to -0.1Treatment differences (Ambroxol- Placebo
  • Ambroxol Lozenges 20 mg vs Placebo · ANCOVA · p = 0.0201 · Mean difference (final values): -0.3 · 95% CI -0.6 to 0.0Treatment differences (Ambroxol- Placebo
SecondaryAssessment of Redness of the Pharyngeal Mucosa by the Investigator on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation

Assessment of redness of the pharyngeal mucosa by the investigator on a 5-point VRS (normal, slightly red, clearly red, very red, severe inflammation) at pre-dose baseline and at the end-of-study evaluation.

Time frame:
Day 1 and Day 2
Reported as:
Number · percentage of participants
Assessment of Redness of the Pharyngeal Mucosa by the Investigator on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation
percentage of participantsAmbroxol Lozenges 20 mgPlacebo
Day 1_Normal0.00.8
Day 1_Slightly red12.112.8
Day 1_ Clearly red53.250.4
Day 1_Very red29.832.0
Day 1_Severe inflammation4.84.0
Day 2_Normal12.110.5
Day 2_Slightly red66.966.9
Day 2_Clearly red18.521.8
Day 2_Very red2.40.8
Day 2_Severe inflammation0.00.0
Statistical analysis
  • Ambroxol Lozenges 20 mg vs Placebo · Mantel Haenszel · p = 0.9939
  • Ambroxol Lozenges 20 mg vs Placebo · Mantel Haenszel · p = 0.5552
SecondaryAssessment of Patients' Assessment of Effectiveness on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation

Assessment of Patients' Assessment of Effectiveness on a 5-point VRS ("very good", "good", "neither good nor poor", "not very good", "not at all good") at pre-dose baseline and at the end-of-study evaluation

Time frame:
Day 1 and Day 2
Reported as:
Number · percentage of participants
Assessment of Patients' Assessment of Effectiveness on a 5-point VRS at Pre-dose Baseline and at the End-of-study Evaluation
percentage of participantsAmbroxol Lozenges 20 mgPlacebo
Day 1_Very good13.78.0
Day 1_Good58.152.0
Day 1_Neither good nor poor19.418.4
Day 1_Not very good6.516.0
Day 1_Not at all good2.45.6
Day 2_Very good24.314.2
Day 2_Good56.852.2
Day 2_Neither good nor poor14.416.8
Day 2_Not very good3.613.3
Day 2_Not at all good0.93.5
Statistical analysis
  • Ambroxol Lozenges 20 mg vs Placebo · Mantel Haenszel · p = 0.0343
  • Ambroxol Lozenges 20 mg vs Placebo · Mantel Haenszel · p = 0.0119

Adverse events

Collected over From drug administration until end of the treatment, up to 2 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ambroxol Lozenges 20 mg0/124 (0%)0/124 (0%)0/124 (0%)
Placebo0/125 (0%)0/125 (0%)0/125 (0%)

Baseline characteristics

Full Analysis Set (FAS): FAS, which included all patients * who were randomized, * who took at least the first lozenge, * who had Pain Intensity (PI) data of baseline.

Age, Continuous
Age, Continuous(years)Ambroxol Lozenges 20 mgPlaceboTotal
Mean36.0 ± 12.238.4 ± 13.037.2 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Ambroxol Lozenges 20 mgPlaceboTotal
Female6771138
Male5754111
08

Study locations

4 sites
  • Boehringer Ingelheim Investigational Site
    Nanjing, China
  • Boehringer Ingelheim Investigational Site
    Shanghai, China
  • ENT Subsidiary of Fudan University Hospital
    Shanghai, China
  • Boehringer Ingelheim Investigational Site
    Wuhan, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2007 to primary completion in Jan 2008, 5 months.

Results were first posted in Jul 2019, 11 years 6 months after primary completion. A results delay was requested in Apr 2014.

Of 13 phase 3 interventional studies under Pharyngitis, half reached primary completion within 3 months of starting (the median); a quarter within 2 and three quarters within 6. This study's 5 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2007
First posted
Sep 5, 2007
StartActual
Aug 1, 2007
Primary completionActual
Jan 1, 2008
CompletionActual
Jan 1, 2008
Results delay requested
Apr 30, 2014
Results first posted
Jul 11, 2019
Last update
Jul 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00525044
Responsible party
Sponsor
First posted
Sep 5, 2007
Start date
Aug 1, 2007
Primary completion
Jan 1, 2008
Completion
Jan 1, 2008
Results posted
Jul 11, 2019
Last update
Jul 11, 2019

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim Shanghai
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ambroxol

Start the discussion